Luxbright AB (LXB) - Net Assets

Latest as of June 2026: Skr23.41 Million SEK ≈ $2.52 Million USD

Based on the latest financial reports, Luxbright AB (LXB) has net assets worth Skr23.41 Million SEK (≈ $2.52 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr32.25 Million ≈ $3.47 Million USD) and total liabilities (Skr8.85 Million ≈ $951.86K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check LXB PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr23.41 Million
% of Total Assets 72.58%
Annual Growth Rate 27.42%
5-Year Change 30.37%
10-Year Change N/A
Growth Volatility 106.69

Luxbright AB - Net Assets Trend (2015–2025)

This chart illustrates how Luxbright AB's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Luxbright AB.

Annual Net Assets for Luxbright AB (2015–2025)

The table below shows the annual net assets of Luxbright AB from 2015 to 2025. Also explore how fast is Luxbright AB growing its equity to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2025-12-31 Skr26.89 Million
≈ $2.89 Million
-21.35%
2024-12-31 Skr34.20 Million
≈ $3.68 Million
+1.52%
2023-12-31 Skr33.69 Million
≈ $3.63 Million
+20.89%
2022-12-31 Skr27.86 Million
≈ $3.00 Million
+35.07%
2021-12-31 Skr20.63 Million
≈ $2.22 Million
-46.60%
2020-12-31 Skr38.64 Million
≈ $4.16 Million
+267.91%
2019-12-31 Skr10.50 Million
≈ $1.13 Million
+52.20%
2018-12-31 Skr6.90 Million
≈ $742.52K
+216.06%
2017-12-31 Skr-5.94 Million
≈ $-639.77K
-791.08%
2016-12-31 Skr-667.16K
≈ $-71.80K
-128.00%
2015-12-31 Skr2.38 Million
≈ $256.40K
--

Equity Component Analysis

This analysis shows how different components contribute to Luxbright AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 17373596900.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock Skr16.27 Million 60.49%
Other Comprehensive Income Skr6.37 Million 23.70%
Other Components Skr180.01 Million 669.29%
Total Equity Skr26.89 Million 100.00%

Luxbright AB Competitors by Market Cap

The table below lists competitors of Luxbright AB ranked by their market capitalization.

Company Market Cap
Bellevue Healthcare Trust PLC
LSE:BBH
$1.16 Million
GS TECHS LTD (DI)
F:6Y3
$1.16 Million
Journeo PLC
LSE:JNEO
$1.17 Million
Asia Media Group Bhd
KLSE:0159
$1.17 Million
QUADRO RESOURCES LTD
F:G4O
$1.15 Million
ARMATURA S.A.
RO:ARM
$1.15 Million
Spectra7 Microsystems Inc
V:SEV
$1.15 Million
Borders & Southern Petroleum plc
LSE:BOR
$1.15 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Luxbright AB's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 34,197,000 to 26,895,000, a change of -7,302,000 (-21.4%).
  • Net loss of 19,464,000 reduced equity.
  • Other factors increased equity by 12,162,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Skr-19.46 Million -72.37%
Other Changes Skr12.16 Million +45.22%
Total Change Skr- -21.35%

Book Value vs Market Value Analysis

This analysis compares Luxbright AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.23x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 0.66x to 0.23x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2015-12-31 Skr0.08 Skr0.05 x
2016-12-31 Skr-0.02 Skr0.05 x
2017-12-31 Skr-0.20 Skr0.05 x
2018-12-31 Skr0.24 Skr0.05 x
2019-12-31 Skr0.34 Skr0.05 x
2020-12-31 Skr1.27 Skr0.05 x
2021-12-31 Skr0.68 Skr0.05 x
2022-12-31 Skr0.71 Skr0.05 x
2023-12-31 Skr0.49 Skr0.05 x
2024-12-31 Skr0.33 Skr0.05 x
2025-12-31 Skr0.22 Skr0.05 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Luxbright AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -72.37%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -170.51%
  • • Asset Turnover: 0.29x
  • • Equity Multiplier: 1.46x
  • Recent ROE (-72.37%) is below the historical average (-67.19%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2015 -64.86% -1818.60% 0.02x 2.02x Skr-1.78 Million
2016 0.00% -427.73% 0.06x 0.00x Skr-3.05 Million
2017 0.00% -566.98% 0.13x 0.00x Skr-6.34 Million
2018 -177.67% -875.41% 0.09x 2.18x Skr-12.95 Million
2019 -101.46% -1514.10% 0.05x 1.47x Skr-11.70 Million
2020 -32.05% -2015.86% 0.01x 1.14x Skr-16.25 Million
2021 -87.73% -2482.59% 0.03x 1.16x Skr-20.16 Million
2022 -75.84% -2603.66% 0.03x 1.12x Skr-23.92 Million
2023 -75.33% -2968.90% 0.02x 1.21x Skr-28.74 Million
2024 -51.81% -196.38% 0.21x 1.25x Skr-21.14 Million
2025 -72.37% -170.51% 0.29x 1.46x Skr-22.15 Million

Industry Comparison

This section compares Luxbright AB's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $773,085,954
  • Average return on equity (ROE) among peers: -68.53%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Luxbright AB (LXB) Skr23.41 Million -64.86% 0.38x $1.16 Million
Acarix A/S (ACARIX) $38.17 Million -125.99% 0.27x $26.71 Million
Arcoma AB (ARCOMA) $40.83 Million -24.05% 0.67x $11.70 Million
Bactiguard Holding AB (publ) (BACTI-B) $386.69 Million 4.20% 0.66x $51.95 Million
BICO Group AB (BICO) $6.80 Billion -3.37% 0.43x $165.40 Million
Boule Diagnostics AB (BOUL) $169.99 Million 17.80% 0.65x $10.41 Million
CellaVision AB (CEVI) $183.52 Million 28.78% 0.20x $418.90 Million
Clinical Laserthermia Systems AB (publ) (CLS-B) $43.53 Million -183.31% 0.33x $9.40 Million
Chordate Medical Holding AB (CMH) $29.55 Million -46.39% 0.39x $29.05K
C-Rad AB (publ) (CRAD-B) $29.82 Million -34.38% 0.50x $119.27 Million
Duearity AB (DEAR) $6.06 Million -318.56% 0.99x $331.97K

About Luxbright AB

ST:LXB Sweden Medical Devices
Market Cap
$1.16 Million
Skr10.73 Million SEK
Market Cap Rank
#30604 Global
#707 in Sweden
Share Price
Skr0.05
Change (1 day)
-2.26%
52-Week Range
Skr0.05 - Skr0.76
All Time High
Skr3.85
About

Luxbright AB (publ), a technology company, develops, manufactures, and sells microfocus x-ray tubes and sources for industrial and non-destructive testing applications worldwide. It also provides Luxbright IX1, an integrated x-ray source product; and custom-made x-ray tubes. Luxbright AB (publ) was incorporated in 2012 and is headquartered in Västra Frölunda, Sweden.